Technology Bundle ID

Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression

Linked ID
Lead Inventors
Craig Thomas (NCATS)
Carlos Zarate (NIMH)
Irving Wainer (NIA)
Panos Zanos (University of Maryland)
Patrick Morris (NCATS)
Ruin Moaddel (NIA)
Todd Gould (University of Maryland)
This technology includes the identification and use of a ketamine metabolite, (2R,6R)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexanone (HNK), for the treatment of depression. Ketamine is an NMDA receptor antagonist that exerts a rapid and sustained antidepressant and anti-suicidal effect. However, even low doses of ketamine has addictive and psychomimetic effects. The downstream metabolite, (2R,6R)-HNK, does not inhibit the NMDA receptor but recapitulates the antidepressant and anti-suicidal effect of ketamine. Further clinical work could establish a ketamine metabolite, such as (2R,6R)-HNK, for the treatment of depression.
Commercial Applications
Further work with the product (2R,6R)-hydroxynorketamine (HNK) could establish its use for the treatment of depression.
Competitive Advantages
While ketamine has already been demonstrated as a robust and acute antidepressant, its use is limited due to multiple liabilities, including its addictive potential. The use of ketamine metabolites, including (2R,6R)-HNK, retains all of the antidepressant effects of ketamine without the associated liabilities.

Request More Info

Licensing Contact: